BioSenic S.A. (BIOS.BR)

EUR 0.0

(7.69%)

EBITDA Summary of BioSenic S.A.

  • BioSenic S.A.'s latest annual EBITDA in 2023 was -6.79 Million EUR , down -199.91% from previous year.
  • BioSenic S.A.'s latest quarterly EBITDA in 2024 Q2 was -180.5 Thousand EUR , down 0.0% from previous quarter.
  • BioSenic S.A. reported an annual EBITDA of -2.25 Million EUR in 2022, up 80.8% from previous year.
  • BioSenic S.A. reported an annual EBITDA of -864 Thousand EUR in 2021, up 18.45% from previous year.
  • BioSenic S.A. reported a quarterly EBITDA of -180.5 Thousand EUR for 2024 Q1, up 87.95% from previous quarter.
  • BioSenic S.A. reported a quarterly EBITDA of N/A for 2023 FY, down -224.27% from previous quarter.

Annual EBITDA Chart of BioSenic S.A. (2023 - 2012)

Historical Annual EBITDA of BioSenic S.A. (2023 - 2012)

Year EBITDA EBITDA Growth
2023 -6.79 Million EUR -199.91%
2022 -2.25 Million EUR 80.8%
2021 -864 Thousand EUR 18.45%
2020 -14.83 Million EUR -63.21%
2019 -6.69 Million EUR 32.26%
2018 -13.13 Million EUR -13.09%
2017 -11.65 Million EUR 4.28%
2016 -12.16 Million EUR -1.27%
2015 -13.06 Million EUR -132.74%
2014 -5.18 Million EUR -47.94%
2013 -3.5 Million EUR -6.41%
2012 -3.15 Million EUR 0.0%

Peer EBITDA Comparison of BioSenic S.A.

Name EBITDA EBITDA Difference
Nicox S.A. -16.23 Million EUR 58.148%
European Medical Solutions 59 Thousand EUR 11618.644%
FERMENTALG -10.51 Million EUR 35.338%
argenx SE -199.5 Million EUR 96.594%
Celyad Oncology SA -7.76 Million EUR 12.457%
Hyloris Pharmaceuticals SA -14.98 Million EUR 54.633%
Onward Medical N.V. -35.23 Million EUR 80.712%
Oxurion NV -16.72 Million EUR 59.376%
PHAXIAM Therapeutics S.A. -22.93 Million EUR 70.362%
Financière de Tubize SA 184.57 Thousand EUR 3782.052%
UCB SA 1.26 Billion EUR 100.536%